复发缓解型多发性硬化症患者接受重组人干扰素β-1b治疗的前90天内病情加重的发生率。

Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing-remitting multiple sclerosis.

作者信息

Khan O A, Hebel J R

机构信息

Department of Neurology, University of Maryland School of Medicine, and Veterans Affairs Medical Center, Baltimore, MD 21201, USA.

出版信息

Ann Neurol. 1998 Jul;44(1):138-9. doi: 10.1002/ana.410440123.

DOI:10.1002/ana.410440123

PMID:9667604

Abstract

Interferon beta-1b (IFNbeta-1b) is effective in reducing the frequency of exacerbations in patients with relapsing-remitting multiple sclerosis (RRMS). Recently, a study suggested that treatment with IFNbeta-1b may place MS patients at risk of exacerbations by increasing interferon-gamma (IFNgamma)-secreting cells in the blood early after onset of treatment. We conducted a retrospective study in 192 RRMS patients treated with IFNbeta-1b. We did not observe an increase in the frequency of exacerbations early after the onset of treatment and suggest that the IFNgamma-secreting cell surge linked to the onset of treatment with IFNbeta-1b may not be clinically significant.

摘要

干扰素β-1b（IFNβ-1b）可有效降低复发缓解型多发性硬化症（RRMS）患者的病情加重频率。最近，一项研究表明，IFNβ-1b治疗可能会使MS患者在治疗开始后早期血液中分泌干扰素γ（IFNγ）的细胞增加，从而面临病情加重的风险。我们对192例接受IFNβ-1b治疗的RRMS患者进行了一项回顾性研究。我们没有观察到治疗开始后早期病情加重频率增加，并表明与IFNβ-1b治疗开始相关的分泌IFNγ细胞激增可能在临床上并不显著。